Nuvalent

Yahoo Finance • last month

Nuvalent’s SWOT analysis: oncology innovator’s stock faces pivotal year

Nuvalent, Inc. (NASDAQ:NUVL), a biopharmaceutical company focused on developing precision cancer therapies, stands at a critical juncture in its journey to bring novel treatments to market. With a robust pipeline and upcoming catalysts, Nu... Full story

Yahoo Finance • last month

Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

CAMBRIDGE, Mass., Aug. 13, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that... Full story

Yahoo Finance • 2 months ago

Nuvalent Inc-A (NASDAQ:NUVL) Reports Q2 2025 Earnings Miss with Focus on Oncology Pipeline Progress

Nuvalent Inc-A (NASDAQ:NUVL [https://www.chartmill.com/stock/quote/NUVL]) reported its second-quarter 2025 financial results, with earnings per share (EPS) of -$1.31, slightly missing analyst estimates of -$1.26. Revenue for the quarter ca... Full story

Yahoo Finance • 2 months ago

Nuvalent initiates rolling NDA submission for ROS1-positive NSCLC drug

CAMBRIDGE, Mass. - Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company with a market capitalization of $5.5 billion, has initiated a rolling New Drug Application (NDA) submission for zidesamtinib, its ROS1-selective in... Full story

Yahoo Finance • 3 months ago

Goldman Sachs initiates coverage on Nuvalent stock with Buy rating

Investing.com - Goldman Sachs initiated coverage on Nuvalent (NASDAQ:NUVL) with a Buy rating and a price target of $105.00, according to a research note released Monday. The company, currently valued at $5.5 billion, maintains strong fin... Full story

Yahoo Finance • 3 months ago

Nuvalent chief development officer Noci sells $314k in shares

NUVL Chief Development Officer Darlene Noci sold a total of 4,000 shares of Nuvalent, Inc. (NASDAQ: NUVL) Class A Common Stock on June 26, 2025, for approximately $314,825. The shares were sold in multiple transactions at prices ranging fr... Full story

Yahoo Finance • 3 months ago

Nuvalent price target raised to $140 from $125 at Leerink

Leerink raised the firm’s price target on Nuvalent (NUVL) to $140 from $125 and keeps an Outperform rating on the shares. Nuvalent’s zidesamtinib has demonstrated a best in class profile in the competitive ROS1 landscape, driven by “unprec... Full story

Yahoo Finance • 3 months ago

Nuvalent price target raised to $130 from $110 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Nuvalent (NUVL) to $130 from $110 and keeps a Buy rating on the shares. The company reported positive topline results from the Phase 1/2 ARROS-1 study evaluat... Full story

Yahoo Finance • 3 months ago

Nuvalent plans FDA submission for lung cancer drug zidesamtinib

CAMBRIDGE, Mass. - Nuvalent, Inc. (NASDAQ:NUVL), a $5.4 billion market cap biotechnology company with strong financial health according to InvestingPro metrics, plans to initiate a rolling New Drug Application (NDA) submission in July 2025... Full story

Yahoo Finance • 3 months ago

Nuvalent's SWOT analysis: brain-penetrant TKIs poised to reshape NSCLC stock

Nuvalent , Inc. (NASDAQ:NUVL), a clinical-stage biotechnology company valued at $5.59 billion, is making waves in the oncology space with its innovative approach to developing brain-penetrant tyrosine kinase inhibitors (TKIs) for non-small... Full story

Yahoo Finance • 6 months ago

Is Nuvalent (NUVL) the Best Debt Free Mid Cap Stock to Buy Now?

We recently compiled a list of the 10 Best Debt Free Mid Cap Stocks to Buy Now. In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against the other debt free mid cap stocks. Debt-free mid-cap stocks... Full story

Yahoo Finance • 6 months ago

Why Nuvalent (NUVL) Is Among the Best Mid Cap Biotech Stocks to Buy

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against the other best mid cap biotech stocks to buy. Is the Biotech Sect... Full story

Yahoo Finance • last year

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib and NVL-655 Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical tri... Full story

Yahoo Finance • last year

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Publication provides comprehensive assessment of NVL-655's preclinical activity and includes preliminary clinical case studies CAMBRIDGE, Mass., Sept. 13, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceuti... Full story

Yahoo Finance • 2 years ago

13 Best Short Squeeze Stocks To Buy Now

In this piece, we will take a look at the 13 best short squeeze stocks to buy now. If you want to skip our primer on short squeezing, and some of the greatest short squeezes in history, then you can take a look at the 5 Best Short Squeeze... Full story

Yahoo Finance • 3 years ago

12 Best Small-Cap Healthcare Stocks To Buy Now

In this article, we discuss 12 best small-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Small-Cap Healthcare Stocks to Buy Now. Macroeconomic headwinds and recessionary concerns will... Full story